Evaluation of respiratory tract bacterial co-infections in SARS-CoV-2 patients with mild or asymptomatic infection in Lagos, Nigeria.
Bacterial pathogens
COVID-19
Co-infection
SARS-CoV-2
Severity
Journal
Bulletin of the National Research Centre
ISSN: 2522-8307
Titre abrégé: Bull Natl Res Cent
Pays: Germany
ID NLM: 101755158
Informations de publication
Date de publication:
2022
2022
Historique:
received:
17
02
2022
accepted:
12
04
2022
entrez:
26
4
2022
pubmed:
27
4
2022
medline:
27
4
2022
Statut:
ppublish
Résumé
A common complication of any respiratory disease by a virus could be a secondary bacterial infection, which is known to cause an increase in severity. It is, however, not clear whether the presence of some opportunistic pathogens called pathobionts contributes to the severity of the disease. In COVID-19 patients, undetected bacterial co-infections may be associated with the severity of the disease. Therefore, we investigated the implications of bacterial co-infections in COVID-19 cases. This is a cross-sectional study that involved archived specimens collected from nasopharyngeal samples of 150 people for COVID-19 screening in Lagos. DNA extraction from the samples was carried out to determine the presence of five respiratory bacterial pathogens using nested real-time PCR, and data were analysed using the Chi-square test. Of the 150 samples collected, 121 (80.7%) were positive for SARs-CoV-2 infection and 29 were negative. The proportion of patients with bacteria co-infection in COVID-19-negative, asymptomatic, and mild cases were 93.1%, 70.7%, and 67.5%, respectively. There was no statistically significant difference between mild COVID-19 conditions and bacteria co-infection ( The current study shows that bacterial co-infection and superinfection with COVID-19 are not associated with mild and asymptomatic COVID-19 cases in our setting. However, given the high prevalence of
Sections du résumé
Background
UNASSIGNED
A common complication of any respiratory disease by a virus could be a secondary bacterial infection, which is known to cause an increase in severity. It is, however, not clear whether the presence of some opportunistic pathogens called pathobionts contributes to the severity of the disease. In COVID-19 patients, undetected bacterial co-infections may be associated with the severity of the disease. Therefore, we investigated the implications of bacterial co-infections in COVID-19 cases.
Results
UNASSIGNED
This is a cross-sectional study that involved archived specimens collected from nasopharyngeal samples of 150 people for COVID-19 screening in Lagos. DNA extraction from the samples was carried out to determine the presence of five respiratory bacterial pathogens using nested real-time PCR, and data were analysed using the Chi-square test. Of the 150 samples collected, 121 (80.7%) were positive for SARs-CoV-2 infection and 29 were negative. The proportion of patients with bacteria co-infection in COVID-19-negative, asymptomatic, and mild cases were 93.1%, 70.7%, and 67.5%, respectively. There was no statistically significant difference between mild COVID-19 conditions and bacteria co-infection (
Conclusions
UNASSIGNED
The current study shows that bacterial co-infection and superinfection with COVID-19 are not associated with mild and asymptomatic COVID-19 cases in our setting. However, given the high prevalence of
Identifiants
pubmed: 35469122
doi: 10.1186/s42269-022-00811-2
pii: 811
pmc: PMC9022018
doi:
Types de publication
Journal Article
Langues
eng
Pagination
115Informations de copyright
© The Author(s) 2022.
Déclaration de conflit d'intérêts
Competing interestsThe authors declare that they have no competing interests.
Références
Front Immunol. 2017 Dec 07;8:1678
pubmed: 29270167
Front Med (Lausanne). 2020 Aug 05;7:420
pubmed: 32850912
Clin Microbiol Infect. 2021 Feb;27(2):297-298
pubmed: 32822882
J Adv Res. 2020 Mar 16;24:91-98
pubmed: 32257431
J Virol. 2006 Feb;80(4):1629-36
pubmed: 16439519
FASEB J. 2016 Jun;30(6):2426-34
pubmed: 26979086
Cytokine. 2020 Feb;126:154895
pubmed: 31706200
Nat Rev Microbiol. 2017 May;15(5):259-270
pubmed: 28316330
Front Microbiol. 2017 Jun 23;8:1041
pubmed: 28690590
J Med Virol. 2020 Sep;92(9):1549-1555
pubmed: 32196707
Vaccine. 2021 Sep 15;39(39):5641-5649
pubmed: 34446318
IUBMB Life. 2020 Oct;72(10):2097-2111
pubmed: 32770825
Pneumonia (Nathan). 2021 Apr 25;13(1):5
pubmed: 33894790
BMC Infect Dis. 2020 Sep 1;20(1):646
pubmed: 32873235
BMC Infect Dis. 2018 Dec 7;18(1):637
pubmed: 30526505
J Infect Dis. 2003 Dec 15;188(12):1928-39
pubmed: 14673774
FEMS Immunol Med Microbiol. 2007 Jun;50(1):112-8
pubmed: 17439541
Laryngoscope. 2009 Jul;119(7):1406-11
pubmed: 19434681
ISME J. 2016 Jan;10(1):97-108
pubmed: 26151645
BMC Infect Dis. 2021 Jul 5;21(1):647
pubmed: 34225644
Front Microbiol. 2019 Dec 03;10:2752
pubmed: 31849894
Viruses. 2019 Jan 09;11(1):
pubmed: 30634396
Front Microbiol. 2020 Aug 25;11:2079
pubmed: 32983056
GMS Hyg Infect Control. 2015 Apr 15;10:Doc06
pubmed: 25914868
Front Immunol. 2018 Nov 16;9:2640
pubmed: 30505304
Eur J Case Rep Intern Med. 2020 Apr 20;7(5):001656
pubmed: 32399452
Nat Microbiol. 2020 Nov;5(11):1408-1417
pubmed: 32724171
Int J Infect Dis. 2020 Aug;97:236-239
pubmed: 32565366
Emerg Microbes Infect. 2020 Dec;9(1):605-615
pubmed: 32178586
Nature. 2020 Dec;588(7837):315-320
pubmed: 32846427
SN Compr Clin Med. 2020;2(7):874-876
pubmed: 32838138
PLoS One. 2021 Jan 11;16(1):e0243271
pubmed: 33428634
Virus Res. 2010 Apr;149(1):1-9
pubmed: 20093154
BMJ Open. 2020 Oct 6;10(10):e040129
pubmed: 33028563
Nat Rev Immunol. 2020 Jun;20(6):363-374
pubmed: 32346093
Front Public Health. 2020 Apr 29;8:152
pubmed: 32411652
Curr Top Microbiol Immunol. 2014;385:327-56
pubmed: 25027822
Am J Respir Crit Care Med. 2020 Jun 1;201(11):1372-1379
pubmed: 32242738